Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the dosing of the first healthy volunteer in its randomized, double-blind, placebo-controlled, Phase I trial Debio 1453-101 (NCT07035769) ‘A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults’. Debiopharm's Debio ...

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — is a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for the 10th year in a row. Among the vendors evaluated, Laserfiche ranks highest overall in usability. Download a copy of the report here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723109668/en/Laserfiche is a Leader for ...